Show simple item record

dc.contributor.authorHeather L. Davis
dc.contributor.authorSuparto, Irma
dc.contributor.authorWeeratnaa, Risini
dc.contributor.authorJumintartod
dc.contributor.authorIskandriatic, Diah
dc.contributor.authorPawitri, Dyah
dc.contributor.authorChamzaha, Siti
dc.contributor.authorMa'rufd, Amir
dc.contributor.authorNented, Citrakasih
dc.contributor.authorPawitric, Dyah
dc.contributor.authorArthur M. Krieg
dc.contributor.authorHeriyantod
dc.contributor.authorWillie Smits
dc.contributor.authorSajuthi, Dondin
dc.date.accessioned2010-06-08T07:00:58Z
dc.date.available2010-06-08T07:00:58Z
dc.date.issued2010
dc.identifier.urihttp://repository.ipb.ac.id/handle/123456789/27850
dc.description.abstractOligonucleotides containing immunostimulatory CpG motifs (CpG ODN) have been shown to be potent Th1-type adjuvants for augmenting antigen-specific responses in mice against hepatitis B surface antigen (HBsAg). The hepatitis B virus (HBV) infects only humans and great apes and appears to exist among wild chimpanzees and orangutans. An outbreak of HBV among orangutans being rehabilitated for re-introduction to the jungle caused the death of several animals. A prophylactic vaccination program revealed that orangutans are quite hypo-responsive to a current commercial vaccine compared to results obtained previously in humans and chimpanzees. Addition of CpG ODN to hepatitis B vaccine greatly increased the seroconversion rate and the titers of antibody against HBsAg (anti-HBs). This is the first demonstration of CpG DNA in a great ape and the results have important implications for the vaccination of humans against HBV and other diseases. Author Keywords : Non-human primate; Infectious immunity — virus; Hepatitis B vaccine; Adjuvantid
dc.publisherIPB (Bogor Agricultural University)
dc.titleCpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutansid


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record